13F Pro

SEC Form 4 reporting owner

Levy Adam D.

Levy Adam D. has filed 4 Form 4 transactions reported between January 14, 2026 and August 4, 2026, as Chief Financial Officer of Acrivon Therapeutics, Inc..

Name as filed: Levy Adam D.

Open-market buys, 24 mo
$15K
1 lines
Open-market sales, 24 mo
$2K
1 lines
Companies
1
with Form 4 filings
Latest transaction
Aug 4, 2026
transaction date

Roles and reported holdings

  • ACRVAcrivon Therapeutics, Inc.
    Jan 14, 2026 – Aug 4, 2026

    Chief Financial Officer

    Held directly66,008 sh as of Aug 4, 2026 · Form 4

    24 months: $15K bought · $2K sold

Transaction history

All 4 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 4, 2026ACRVChief Financial OfficerOpen-market saleCode S · direct1,142$2K@ $1.57Form 4
May 18, 2026ACRVChief Financial OfficerGrant or awardCode A · direct46,167—Form 4
Mar 1, 2026ACRVChief Financial OfficerGrant or awardCode A · direct132,925—Form 4
Jan 14, 2026ACRVChief Financial OfficerOpen-market purchaseCode P · direct8,832$15K@ $1.70Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.